Dynavax Technologies Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
405
- Stock Symbol
-
DVAX
- Investments
-
2
- Share Price
-
$10.42
- (As of Tuesday Closing)
Dynavax Technologies General Information
Description
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Contact Information
Website
www.dynavax.comCorporate Office
- 2100 Powell Street
- Suite 720
- Emeryville, CA 94608
- United States
Corporate Office
- 2100 Powell Street
- Suite 720
- Emeryville, CA 94608
- United States
Dynavax Technologies Stock Performance
As of 20-May-2025, Dynavax Technologies’s stock price is $10.42. Its current market cap is $1.25B with 120M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.42 | $9.83 | $9.22 - $14.63 | $1.25B | 120M | 2.69M | -$0.49 |
Dynavax Technologies Financials Summary
As of 31-Mar-2025, Dynavax Technologies has a trailing 12-month revenue of $295M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,149,782 | 1,164,851 | 1,344,138 | 1,028,829 |
| Revenue | 294,621 | 277,246 | 232,284 | 722,683 |
| EBITDA | (75,329) | 9,237 | (22,327) | 299,787 |
| Net Income | (60,069) | 27,309 | (6,389) | 293,156 |
| Total Assets | 945,928 | 986,256 | 997,096 | 985,850 |
| Total Debt | 286,028 | 254,417 | 256,914 | 258,010 |
Dynavax Technologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Dynavax Technologies Comparisons
Industry
Financing
Details
Dynavax Technologies Competitors (42)
One of Dynavax Technologies’s 42 competitors is TC Biopharm, a Formerly VC-backed company based in Motherwell, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TC Biopharm | Formerly VC-backed | Motherwell, United Kingdom | ||||
| Coherus Biosciences | Formerly VC-backed | Redwood City, CA | ||||
| Immunocore | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Agenus | Formerly VC-backed | Lexington, MA |
Dynavax Technologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Dynavax Technologies Patents
Dynavax Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240165215-A1 | Immunogenicity of a cpg-adjuvanted recombinant plague vaccine | Pending | 30-Jun-2022 | ||
| EP-4486360-A2 | Immunogenic compositions comprising a recombinant neuraminidase and cpg oligonucleotide adjuvant, and uses thereof | Pending | 01-Mar-2022 | ||
| CA-3241245-A1 | Immunogenicity of a cpg-adjuvanted herpes zoster vaccine | Pending | 23-Dec-2021 | ||
| AU-2022420617-A1 | Immunogenicity of a cpg-adjuvanted herpes zoster vaccine | Pending | 23-Dec-2021 | ||
| EP-4452312-A1 | Immunogenicity of a cpg-adjuvanted herpes zoster vaccine | Pending | 23-Dec-2021 | A61K39/25 |
Dynavax Technologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Dynavax Technologies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Dynavax Technologies Acquisitions (2)
Dynavax Technologies’s most recent deal was a Merger/Acquisition with Symphony Dynamo for . The deal was made on 04-Jan-2010.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Symphony Dynamo | 04-Jan-2010 | Merger/Acquisition | Pharmaceuticals | ||
| Rhein Biotech | Merger/Acquisition | Biotechnology |
Dynavax Technologies ESG
Risk Overview
Risk Rating
Updated February, 12, 2025
30.12 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Biotechnology
Subindustry
of 365
Rank
Percentile
Dynavax Technologies FAQs
-
When was Dynavax Technologies founded?
Dynavax Technologies was founded in 1996.
-
Where is Dynavax Technologies headquartered?
Dynavax Technologies is headquartered in Emeryville, CA.
-
What is the size of Dynavax Technologies?
Dynavax Technologies has 405 total employees.
-
What industry is Dynavax Technologies in?
Dynavax Technologies’s primary industry is Drug Discovery.
-
Is Dynavax Technologies a private or public company?
Dynavax Technologies is a Public company.
-
What is Dynavax Technologies’s stock symbol?
The ticker symbol for Dynavax Technologies is DVAX.
-
What is the current stock price of Dynavax Technologies?
As of 20-May-2025 the stock price of Dynavax Technologies is $10.42.
-
What is the current market cap of Dynavax Technologies?
The current market capitalization of Dynavax Technologies is $1.25B.
-
What is Dynavax Technologies’s current revenue?
The trailing twelve month revenue for Dynavax Technologies is $295M.
-
Who are Dynavax Technologies’s competitors?
TC Biopharm, Coherus Biosciences, Immunocore, Inovio Pharmaceuticals, and Agenus are some of the 42 competitors of Dynavax Technologies.
-
What is Dynavax Technologies’s annual earnings per share (EPS)?
Dynavax Technologies’s EPS for 12 months was -$0.49.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
